# Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Source: https://onco.cc/trials/nct06458712/  
OnCo record `nct06458712` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06458712 as recruiting, last updated 2026-09-02. Enrolment is 180 planned participants, an estimate. Interventions: DSB2455. Primary measures include Number of patients demonstrating dose limiting toxicities and SAEs; Number of patients exhibiting reduction in tumor size.. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06458712
- Phase: 1
- Setting: Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies
- Sponsor: Duke Street Bio Ltd

## Sources

- ClinicalTrials.gov NCT06458712: https://clinicaltrials.gov/study/NCT06458712

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [DSB2455](https://onco.cc/drugs/dsb2455/)

---
JSON: https://onco.cc/api/v1/entities/nct06458712.json